Work is ongoing to recover UK clinical research capacity and capabililty post COVID-19 pandemic (https://sites.google.com/nihr.ac.uk/thefutureofukclinicalresearch/home), but many of the barriers investigators faced pre-pandemic persist. Taking a more patient-centred approach to reform may help apply lessons learned during the pandemic and facilitate ‘building back better’.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989575 | PMC |
| http://dx.doi.org/10.1038/s41416-023-02198-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and evaluation of a single domain antibody targeting folate receptor alpha for radioligand therapy.
J Nanobiotechnology
December 2024
Precirix, Burg. Etienne Demunterlaan 3, Brussels, Matthias, B-1090, Belgium.
Background: Folate receptor alpha (FRα) overexpression is seen in many cancers. Radioligand therapy (RLT) has emerged as a promising tool to target FRα and has been investigated previously, but further progression was limited due to high kidney retention and, subsequently, toxicity. To circumvent this, we present here the development of a [I]I-GMIB-conjugated anti-human FRα (hFRα) single-domain antibody (sdAb), with intrinsically fast renal clearance and concomitant low kidney retention.
View Article and Find Full Text PDFTowards integrated cross-sectoral surveillance of pathogens and antimicrobial resistance: Needs, approaches, and considerations for linking surveillance to action.
Environ Int
October 2024
Centre to Impact AMR, Monash University, Melbourne, Australia; Infection Program, Biomedicine Discovery Institute and Department of Microbiology, Monash University, Melbourne, Australia; RISE: Revitalising Informal Settlements and their Environments, Melbourne, Australia; Securing Antarctica's Environmental Future, Monash University, Melbourne, Australia. Electronic address:
Article Synopsis
- Pathogenic and antimicrobial-resistant (AMR) germs are spread between humans, animals, and the environment, making diseases harder to treat.
- We need better ways to track these germs by combining efforts from different fields instead of working separately.
- The text suggests improving detection methods and creating strong systems to share information about these germs, helping everyone stay healthier.
Complement in human disease: approved and up-and-coming therapeutics.
Lancet
January 2024
Complement and Inflammation Research Section, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address:
The complement system is recognised as a protector against blood-borne pathogens and a controller of immune system and tissue homoeostasis. However, dysregulated complement activity is associated with unwanted or non-resolving immune responses and inflammation, which induce or exacerbate the pathogenesis of a broad range of inflammatory and autoimmune diseases. Although the merit of targeting complement clinically has long been acknowledged, the overall complement drug approval rate has been modest.
View Article and Find Full Text PDFHow can lessons from the COVID-19 pandemic enhance antimicrobial resistance surveillance and stewardship?
Lancet Infect Dis
August 2023
Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research, New Delhi 110029, India.
COVID-19 demanded urgent and immediate global attention, during which other public health crises such as antimicrobial resistance (AMR) increased silently, undermining patient safety and the life-saving ability of several antimicrobials. In 2019, WHO declared AMR a top ten global public health threat facing humanity, with misuse and overuse of antimicrobials as the main drivers in the development of antimicrobial-resistant pathogens. AMR is steadily on the rise, especially in low-income and middle-income countries across south Asia, South America, and Africa.
View Article and Find Full Text PDFRevitalising cancer trials post-pandemic: time for reform.
Br J Cancer
April 2023
Department of Medical Oncology, Guy's & St Thomas NHS Foundation Trust, London, UK.
The COVID-19 pandemic posed significant risk to the health of cancer patients, compromised standard cancer care and interrupted clinical cancer trials, prompting dramatic streamlining of services. From this health crisis has emerged the opportunity to carry forward an unexpected legacy of positive reforms to clinical cancer research, where conventionally convoluted approvals processes, inefficient trial design, procedures and data gathering could benefit from the lessons in rationalisation learned during the pandemic.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!